What is Aignostics?
Aignostics is an international interdisciplinary team dedicated to powering the next generation of precision medicine and advancing the fields of AI and pathology. The company leverages cutting-edge artificial intelligence and deep pathology expertise to develop solutions that enhance diagnostic accuracy and personalize treatment strategies. By integrating AI with pathological analysis, Aignostics aims to revolutionize how diseases are detected and managed, paving the way for more effective and targeted patient care.
How much funding has Aignostics raised?
Aignostics has raised a total of $48M across 2 funding rounds:
Series A
$14M
Series B
$34M
Series A (2022): $14M with participation from Boehringer Ingelheim Venture Fund, Wellington Partners, VC Fonds Technologie, and High-Tech Gründerfonds
Series B (2024): $34M led by Boehringer Ingelheim Venture Fund, ATHOS Holding, CARMA FUND Management, IBB Ventures, Wellington Partners, and Mayo Clinic
Key Investors in Aignostics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients, focusing on first-in-class, disease-modifying therapeutics.
Wellington Partners
Wellington Partners is a leading European venture capital firm that invests in early- and growth-stage life science companies, supporting entrepreneurs in transforming innovative ideas into successful businesses.
High-Tech Gründerfonds
High-Tech Gründerfonds is a pre-seed and seed investor focusing on high-tech startups, offering a strong network and deep tech expertise to shape the future.
What's next for Aignostics?
The recent major strategic investment of $34M positions Aignostics for accelerated growth and further innovation in the precision medicine landscape. This capital infusion is expected to fuel the expansion of its AI-powered pathology platform, enhance research and development initiatives, and broaden its market reach. With a clear focus on advancing AI in healthcare, Aignostics is poised to make significant contributions to the field, potentially leading to new breakthroughs in disease diagnosis and treatment, and solidifying its role as a key player in the future of precision medicine.
See full Aignostics company page
